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ABSTRACT
Introduction: The efficacy of lowering
intraocular pressure (IOP) and safety of
switching to travoprost/timolol fixed
combination ophthalmic solution (Duotrav,
Alcon Laboratories, Inc., Fort Worth, TX, USA)
in patients with primary open-angle glaucoma,
normal tension glaucoma or ocular
hypertension undergoing prostaglandin analog
(PGA) monotherapy was investigated.
Methods: Patients treated with travoprost,
latanoprost, tafluprost, or bimatoprost for
C3 months and requiring additional
medication were switched to Duotrav without
washout. Baseline IOP was calculated from
measurements at two visits during PGA
monotherapy. IOP reductions at 4, 8, and
12 weeks after switching to Duotrav and
adverse events were assessed.
Results: Of 162 patients enrolled, 157 patients
(96.9%) with C4 weeks of follow-up after
switching to Duotrav were analyzed. The mean
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IOP decreased significantly (baseline =
16.3 ± 3.1 mmHg; 4 weeks = 14.6 ± 3.1 mmHg,
8 weeks = 14.7 ± 3.3 mmHg, 12 weeks =
14.6 ± 3.2 mmHg; all P\0.0001). When study
eyes were divided into three groups according to
baseline IOP (C19 mmHg: 33 eyes, 21.0%; C15 to
\19mmHg: 78 eyes, 49.7%;\15 mmHg: 46 eyes,
29.3%), all groups showed significant IOP
reductions (P= 0.0324* P\0.0001) after
switching to Duotrav. Twenty-seven of 166
patients (16.3%) in the safety analysis
experienced adverse events and 26/166 patients
(15.7%) experienced adverse events, for which a
relationship to Duotrav could not be ruled out.
Adverse events in five patients led to treatment
discontinuation (eye pruritus; eye irritation;
increased blood pressure and rash; increased
blurred vision; deepening of the eyelid sulcus
and blepharoptosis). Twelve weeks after
treatment switching, eyelash changes, blepharal
pigmentation and deepening of the eyelid sulcus
occurred in 42 (26.8%), 29 (18.5%), and 13 (8.3%)
cases, respectively, among 157 patients with
follow-up. There was no significant worsening
from baseline for superficial punctate keratopathy
(SPK) or conjunctival hyperemia after switching
(SPK score: baseline= 0.58± 1.31; 12 weeks=
0.92± 1.76, P= 0.1819; conjunctival hyperemia
score: baseline= 0.41± 0.64; 12 weeks=
0.49± 0.63, P= 0.3774).
Conclusion: Our findings confirm that
switching to Duotrav in PGA monotherapy
patients shows IOP-lowering effect with
minimal safety concerns.
Funding: Japan Association of Health Service
and Alcon Japan. Ltd.
Trial registration: UMIN Clinical Trials
Registry identifier, UMIN000007028.
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INTRODUCTION
Lowering intraocular pressure (IOP) is the
only evidence-based strategy for managing
patients with glaucoma and prostaglandin
analogs (PGAs) that effectively lower IOP
represent the current first-line topical
ophthalmic treatment for the disease [1].
However, visual field defects associated with
glaucoma can continue to progress even
after IOP is lowered to a specific target
level [2]. Nearly, 40% of patients who have
experienced a significant IOP reduction with
PGA therapy require a further reduction and
start to receive an additional topical
ophthalmic medication [3, 4]. Combination
regimens using multiple different
ophthalmic solutions are less convenient
for patients and increase their burden
because patients need to take their
prescribed ophthalmic solutions several
times a day with a wait of at least 5 min
between taking different solutions [5–7]. In
contrast, fixed drugs of a PGA and a
b-blocker produce a similar additive
IOP-lowering effect without increasing the
burden on patients and thus may be
advantageous in preventing the risk of
becoming non-adherent after the addition
of a second drug [8].
Previous studies have reported significant
IOP reductions after switching from PGA
monotherapy (latanoprost, travoprost, or
bimatoprost) to fixed drugs containing the
corresponding PGA [9–11]. However, these
studies mainly included patients with
open-angle glaucoma with a high baseline IOP
([19 mmHg) or those with ocular hypertension
(OH). No studies have evaluated the efficacy of
travoprost/timolol fixed combination
(Duotrav, Alcon Laboratories, Inc., Fort
Worth, TX, USA) therapy in patients whose
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IOP has already been lowered to B19 mmHg
with PGA monotherapy [10, 12, 13].
Because visual field defects progress
steadily even in normal tension glaucoma
(NTG) [14], a condition where IOP remains
normal, NTG patients are also treated with
PGA-based IOP-lowering therapy [15, 16],
and if visual field defects continue to
progress despite a significant IOP reduction
with initial monotherapy, a second drug is
added [17]. Thus, these patients are also
potential candidates to receive fixed drugs
therapy. However, the efficacy of switching
to a fixed drug therapy has not been
extensively studied in this patient
population.
The four PGAs currently available for the
treatment of glaucoma are travoprost,
latanoprost, tafluprost, and bimatoprost and
for each of these, fixed combination
ophthalmic solutions are commercially
available or have been approved [18]. Among
these solutions, Duotrav which contains
polyquaternium-1 (Polyquad, Alcon
Laboratories, Inc., Fort Worth, TX, USA) as a
preservative is the only one that does not
contain benzalkonium chloride (BAK), a
preservative that increases the risk of corneal
damage [19], when switching from
monotherapy.
In the present study, we investigated
whether patients with open-angle glaucoma,
including NTG, or with OH who had been
treated with one of the four PGAs for at least 3
months and some of whom had an IOP of less
than 19 mmHg would experience a further
reduction in IOP after switching to Duotrav.
Here, we report the efficacy of Duotrav in this
patient population as well as the local and




Patients eligible for the study were aged 20 years
or older, had been diagnosed with primary
open-angle glaucoma (POAG), NTG, or OH,
and were judged by their treating doctors to
require additional ophthalmic medication due
to the progression of visual field defects or
uncontrolled IOP despite continued treatment
with one of four PGAs for at least 3 months.
Exclusion criteria: (1) a mean deviation (MD)
of less than -20 dB by visual field testing; (2) a
history of hypersensitivity to b-blockers or a
contraindication to b-blockers (e.g., bronchial
asthma and uncontrolled heart failure); (3) the
presence of chronic or recurrent uveitis, scleritis
or corneal herpes; (4) a history of ocular trauma,
intraocular surgery or laser treatment within
3 months prior to the baseline evaluation; (5)
any condition that would preclude accurate IOP
measurement by applanation tonometry; (6)
the use of ophthalmic corticosteroids; (7)
serious ocular complications; (8) pregnancy or
lactation; and (9) severe dementia. Patients
whose participation in the study was deemed
inappropriate by their treating doctors were also
excluded. Gender and the presence of dry eyes
were not considered when enrolling patients.
Prior to any study procedures, the protocol
and all aspects of the study were reviewed and
approved by the ethics committee of Kitamachi
Clinic, Tohoku University Hospital, Juntendo
University Urayasu Hospital, the Jikei
University School of Medicine, Nakano
General Hospital, Fussa Hospital, Fukui-ken
Saiseikai Hospital and Minami-Matsuyama
Hospital. This study was registered with the
University Hospital Medical Information
Network (UMIN), number UMIN000007028.
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Among potential subjects who met all of the
inclusion and none of the exclusion criteria,
only those who signed informed consent forms
through the process according to the principles
of the Helsinki declaration were enrolled in the
study.
Procedures
This was a prospective multicenter open-label
study. Patients requiring a further IOP
reduction in the opinion of their treating
doctors were switched from PGA monotherapy
to travoprost/timolol maleate fixed
combination (Duotrav) without having a
period of washout from the previous PGA.
One drop of Duotrav was instilled into the
conjunctival sac of one or both eyes in the
morning once daily. Patients underwent
protocol-specified examinations before (at
baseline) and at 4, 8, and 12 weeks after
switching. In each patient, IOP was measured
in duplicate by the same examiner throughout
the study period using the Goldmann
applanation tonometer and the mean of the
two values was used for data analysis. IOP
measurements during follow-up were
performed at the same time of day (±2 h) as
baseline measurements. During each visit, eyes
were examined for superficial punctate
keratopathy (SPK) and conjunctival hyperemia
by slit-lamp microscopy. The degree of SPK was
scored on a 5-point scale from 0 to 4 according
to the cornea diagram of the National Eye
Institute (NEI) classification system [20]. The
degree of conjunctival hyperemia was scored on
a 4-point scale, where 0 = no dilated vessels,
1 = dilation of primarily small vessels,
2 = dilation of small and large vessels, and
3 = significant dilation of small and large
vessels. These assessments were rated by
reference to sample pictures of eyes with SPK
and conjunctival hyperemia that were provided
beforehand. To collect data on adverse events,
doctors asked patients if they had any
symptoms and also examined them for any
signs or symptoms during each visit. Patients
were always asked whether there was irritation,
foreign body sensations, dry feeling or itching
in the patient’s eyes. Examination for eyelash
changes, blepharal pigmentation and
deepening of the eyelid sulcus was also
mandatory. To detect these adverse events,
pictures of eyes were taken every visit and
changes from baseline were recorded.
Examinations were performed according to
each center’s practice and instruments, and
conditions for taking pictures were not
standardized. At the start of Duotrav therapy,
patients were instructed to remove any solution
spilled on the eyelid skin by wiping or washing
their face. At the start and end of the study,
systolic/diastolic blood pressure and pulse rate
were measured.
Statistical Analysis
Primary endpoint was IOP, IOP reduction and
IOP reduction rate from baseline. Secondary
endpoint was safety including the score of SPK
and conjunctival hyperemia.
Patient data including disease subtype and
IOP measurements were collected at each center
were sent to and assembled by Tajimi Iwase Eye
Clinic in an anonymous form. An
ophthalmologist not involved in data
collection (M.S.) validated each case. Patients
who completed at least 4 weeks of follow-up
were included in the analysis.
Baseline IOP was defined as the mean of two
measurements obtained at two visits during
PGA monotherapy. If both eyes were eligible for
the study, the eye with a higher baseline IOP
was chose or, if both eyes had an equal baseline
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IOP, the right eye was selected as the study eye.
Absolute and percent IOP reductions from
baseline were analyzed for study eyes of
patients who were followed up for at least
4 weeks after starting Duotrav therapy using
repeated-measures analysis of variance and
Steel’s multiple comparison test. SPK and
conjunctival hyperemia scores were analyzed
by Steel’s test. Missing values after 4 weeks were
imputed using last observation carried forward
method.
Adverse events for which a relationship to
Duotrav could not be ruled out were graded
according to the following criteria: mild (the
patient recognized the adverse event but could
tolerate the symptom), moderate (the patient
found the symptom interfered with normal
activities and was uncomfortable) and severe
(the symptom was physically disabling and
prevented the patient from working and
normal activities). Eyelash changes, blepharal
pigmentation and deepening of the eyelid
sulcus were analyzed separately and
cumulative incidence rates were calculated.
Overall incidence rate of adverse events was
also calculated. Changes from baseline in blood
pressure, pulse rate were analyzed using the
Kruskal–Wallis test. Statistical analysis was
performed by QOL RD Co., Ltd., and SOC Co.,
Ltd., using JMP9.0 and SAS9.3 (SAS Institute
Inc., Cary, NC, USA) with a two-sided
significance level of 5%.
RESULTS
The study was conducted from August 2011 to
March 2013. Among 166 patients who gave
informed consent for the study, 162 patients
(97.6%) were eligible according to the inclusion
and exclusion criteria. Five of these 162 patients
dropped out within 4 weeks (one developed eye
pruritus, two requested treatment
discontinuation and two missed visits); the
remaining 157 patients (96.9%) with at least 4
weeks of follow-up were included in the
analysis.
The analysis population consisted of 54
males and 103 females with a mean age of
66.6 ± 11.3 years (range 39–88 years). Of these,
60 (38.2%) had POAG, 78 (49.7%) had NTG,
and 19 (12.1%) had OH. There were no
significant differences in age or sex between
the disease subgroups (Table 1). Ten of 157
patients (6.4%) discontinued the study before
12 weeks. Reasons for discontinuation included
blurred vision (1), increased blood pressure and
rash (1), deepening of the eyelid sulcus and
blepharoptosis (1), eye irritation (1), insufficient
IOP-lowering effect (1), patient’s request (4),
and loss to follow-up (1).
After the initiation of travoprost/timolol
maleate fixed combination (Duotrav)
treatment, the mean IOP of eyes included in
the analysis significantly decreased from 16.3 ±
3.1 mmHg at baseline to 14.6 ± 3.1 mmHg at
4 weeks, 14.7 ± 3.3 mmHg at 8 weeks and
14.6 ± 3.2 mmHg at 12 weeks (P\0.0001 for
all time points). The mean percent reduction in
IOP from baseline was 10.3 ± 12.7%, 9.4 ±
14.3%, and 10.1 ± 13.0% at 4, 8, and
12 weeks, respectively.
Individual baseline IOP values had a wide
range from 9.5 to 27.5 mmHg (interquartile
range 14.5 to 18.5 mmHg) and were
C19 mmHg for 33 eyes (21.0%), C15 to \19
mmHg for 78 eyes (49.7%), and\15 mmHg for
46 eyes (29.3%; Fig. 1). We then assessed the
treatment effect by baseline IOP. When study
eyes were divided into three groups according
to baseline IOP (C19 mmHg, C15 to
\19 mmHg, or \15 mmHg), all groups had
significant IOP reductions from baseline at 4,
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8, and 12 weeks after switching to Duotrav
(Fig. 2).
In a multiple regression analysis with IOP
reduction from baseline at 12 weeks after
switching to Duotrav as a dependent variable
and demographic and baseline characteristics
(type of prior PGA, age, gender, treatment
duration, baseline IOP, MD and pattern
standard deviation (PSD) values as
independent variables, the type of PGA used
in prior treatment and baseline IOP had a
significant association (Table 2).
There was no significant worsening of SPK
total scores or conjunctival hyperemia scores
after switching to Duotrav (Table 3). During the
study, 26 of 166 patients (15.7%) experienced
42 adverse events for which a relationship to
Duotrav could not be ruled out. Among the 42
adverse events, 38 in 24 patients were mild in
severity. The remaining four events in four
Table 1 Patient characteristics
Characteristic POAG OH NTG Total
n 60 19 78 157
Male, n (%) 14 (24.6%) 4 (21.1%) 34 (43.6%) 54
Female, n (%) 43 (75.4%) 15 (78.9%) 44 (56.4%) 103
Age, years n = 60 n = 19 n = 78 n = 157
67.5 ± 11.8 (39–88) 68.2 ± 10.8 (47–87) 65.5 ± 11.2 (40–88) 66.6 ± 11.3 (39–88)
Previous PGA, n (%)
Travoprost 23 8 39 70 (44.6%)
Latanoprost 15 5 25 45 (28.7%)
Taﬂuprost 16 4 9 29 (18.5%)
Bimatoprost 6 2 5 13 (8.3%)
Baseline IOP,
mmHg
n = 60 n = 19 n = 78 n = 157
17.9 ± 2.7 (12.0–27.5) 18.8 ± 2.9
(13.5–22.5)
14.5 ± 2.2 (9.5–19.5) 16.3 ± 3.1 (9.5–27.5)
Corneal thickness,
lm



























Data are shown as mean ± standard deviation (range) unless otherwise stated
OH ocular hypertension, IOP intraocular pressure,MD mean deviation, NTG normal tension glaucoma, PGA prostaglandin
analog, POAG primary open-angle glaucoma, PSD pattern standard deviation
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patients were graded as moderate and included
blepharal pigmentation, eye pruritus, eye
irritation, and increased blood pressure.
Blepharal pigmentation was reported during
the 4-week visit together with skin itching and
Duotrav was discontinued at the patient’s
request. Eye pruritus and eye irritation
occurred at 4 and 14 days of treatment,
respectively, and increased blood pressure was
noted during the 4-week visit together with
mild rash. In these three cases, treatment was
discontinued at the doctor’s discretion and all
the events improved or resolved during the
study period. Among the mild events observed,
increased blurred vision (occurring at 8 weeks in
one patient) and deepening of the eyelid sulcus
and blepharoptosis (occurring at 17 days in one
patient) led to treatment discontinuation at the
doctor’s discretion (Table 4).
All 157 eyes with at least 4 weeks of
follow-up underwent serial examinations for
eyelash changes, blepharal pigmentation, and
deepening of the eyelid sulcus, where a change
from baseline was considered an adverse event.
The cumulative incidence was highest for
eyelash changes (42 patients; 26.8%), followed
by blepharal pigmentation (29; 18.5%) and
deepening of the eyelid sulcus (13; 8.3%;
Table 5).
At 12 weeks, there were no significant
changes from baseline in the mean systolic
blood pressure (135.3 ± 17.4 mmHg at baseline
and 132.4 ± 17.5 mmHg at 12 weeks;






















Intraocular pressure  (mmHg)  
Fig. 1 Distribution of baseline intraocular pressure
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(80.2 ± 11.1 and 78.4 ± 10.8 mmHg;
P = 0.5266) or pulse rate (70.8 ± 13.0 and
68.2 ± 12.1 bpm; P = 0.3033) among 151
patients with available data.
DISCUSSION
In patients with POAG, NTG, or OH whose IOP
had been lowered with PGA monotherapy but
who were judged to require an additional
ophthalmic medication, switching to
travoprost/timolol maleate fixed combination
(Duotrav) produced a further reduction in IOP
after 12 weeks of treatment and was not
associated with serious adverse events.
The goal of treating glaucoma is to maintain
visual function.Currently, IOP-lowering therapy
is the only evidence-based treatment and to
prevent the progression of visual field defects, a
greater IOP-lowering effect is needed [21, 22].
Baseline IOP  Baseline 4 weeks 8 weeks 12 weeks 
n = 33 Mean (mmHg) 20.7 17.8 18.0 17.7 
SD (mmHg) 1.9 2.9 3.6 3.7 
P value* vs. baseline  0.0001 <0.0001 <0.0001 
<19 mmHg, n = 78 
Mean (mmHg) 16.5 14.8 14.9 14.7 
SD (mmHg) 1.2 2.3 2.3 2.1 
P value* vs. baseline  <0.0001 <0.0001 <0.0001 
<15 mmHg, n = 46 Mean (mmHg) 12.9 11.8 12.0 12.1 
SD (mmHg) 1.5 1.8 2.2 1.8 
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Baseline                                 4 weeks                             8 weeks                              12 weeks 
Fig. 2 Intraocular pressure reductions after switching by baseline intraocular pressure subgroups. Asterisks repeated-mea-
sures analysis of variance and Steel’s multiple comparison test. IOP intraocular pressure, SD standard deviation
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Among current topical ophthalmic
medications used for the treatment of
glaucoma, PGAs are the most effective in
lowering IOP and are regarded as the first-line
treatment of choice. If the IOP reduction
achieved with first-line monotherapy is
insufficient, combination therapy using
multiple drugs is indicated [3, 4] and in such
cases, fixed drug may be more advantageous for
continuous treatment as they cause less events
that might lead to early discontinuation [5–7].
Although previous studies reported reductions
in IOP after switching from PGA monotherapy
to fixed drug containing the corresponding
PGA, few studies have evaluated the efficacy of
switching from any PGA monotherapy to a
specific fixed drug. Among fixed drugs currently
available, only Duotrav contains
polyquaternium-1 (Polyquad) as a preservative
instead of BAK and therefore patients are not
exposed to the compound. These
considerations led us to design a study to
evaluate the efficacy and safety of switching to
Duotrav in patients maintained on
monotherapy with one of the four PGAs
currently available in Japan (travoprost,
latanoprost, tafluprost, and bimatoprost).
In the present study, patients had a mean
IOP of 16.3 ± 3.1 mmHg at baseline, which was
calculated from measurements at two visits
Table 2 Multiple regression analysis
Factor Degree of freedom Sum of squares F value P value
PGAs 3 106.7065789 8.26 \0.0001
Age 1 1.1326213 0.26 0.6089
Sex 1 5.9941339 1.39 0.2402
Dosing period of PGAs 1 0.0018124 0.00 0.9837
Baseline intraocular pressure 1 68.9170780 16.00 0.0001
Baseline MD value 1 6.8635484 1.59 0.2090
Baseline PSD value 1 11.7128012 2.72 0.1014
MD mean deviation, PGAs prostaglandin analogs, PSD pattern standard deviation
In a multiple regression analysis with IOP reduction from baseline at 12 weeks after switching to Duotrav as a dependent
variable, and demographic and baseline characteristics as independent variables, the type of PGA used in prior treatment and
baseline IOP had a signiﬁcant association. Coefﬁcient of determination [R2] was 0.29
Table 3 Changes in scores of SPK and conjunctival hyperemia over time
Scale Baseline 4 weeks 8 weeks 12 weeks
SPK total scores 0.58 ± 1.31 0.90 ± 1.68 0.88 ± 1.78 0.92 ± 1.76
P value* vs. baseline – 0.1259 0.1616 0.1819
Conjunctival hyperemia scores 0.41 ± 0.64 0.52 ± 0.69 0.45 ± 0.61 0.49 ± 0.63
P value* vs. baseline – 0.3470 0.8215 0.3774
Data are shown as mean ± standard deviation
SPK Superﬁcial punctate keratopathy
* Steel’s test
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during PGA monotherapy. It is not surprising
that the IOP before adding a second drug was
within the normal range [17] because NTG is
dominant in Japan [23]. After switching to
Duotrav, IOP significantly decreased from
baseline at all specified timepoints during the
12-week follow-up period (4, 8, and 12 weeks)
with the mean IOP decreasing to
14.6 ± 3.2 mmHg at 12 weeks. This
corresponded to a mean 10.1% reduction from
the baseline value. PGA therapy reduced IOP by
more than 20% from pretreatment values even
in patients with NTG [24, 25]. The 10%
reduction observed in this study after
Table 4 Adverse events
Adverse events
Mild Moderate Total
Patients included in safety analysis 166 166 166
Number of events (number of cases) 38 (22) 4 (4) 42 (26)
Type n % n % n %
Eye disorders 34 – 3 – 37 –
Eye lid sulcus deepened 8 4.8 8 4.8
Growth of eyelashes 5 3 5 3
Blepharal pigmentation 3 1.8 1 0.6 4 2.4
Superﬁcial punctate keratopathy 4 2.4 4 2.4
Dry eyes 3 1.8 3 1.8
Foreign body sensation in eyes 2 1.2 2 1.2
Eyelid ptosis 1 0.6 1 0.6
Eye irritation 1 0.6 1 0.6 2 1.2
Eye pruritus 1 0.6 1 0.6 2 1.2
Iritis 1 0.6 1 0.6
Keratitis 1 0.6 1 0.6
Vision blurred 1 0.6 1 0.6
Visual acuity reduced 1 0.6 1 0.6
Conjunctival hyperemia 1 0.6 1 0.6
Corneal epitheliopathy 1 0.6 1 0.6
Other 4 – 1 – 5 –
Blood pressure increased 1 0.6 1 0.6
Headache 1 0.6 1 0.6
Herpes zoster 1 0.6 1 0.6
Itchy skin 1 0.6 1 0.6
Rash 1 0.6 1 0.6
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switching to Duotrav is similar to those
reported previously in NTG populations [26,
27]. The absolute reduction of about 1.5 mmHg
associated with switching to Duotrav seems to
represent a meaningful treatment benefit,
considering the findings from the Early
Manifest Glaucoma Trial where every 1 mmHg
of IOP reduction has patient benefit [21].
Because individual baseline IOP values
showed a wide variation, we assessed the
treatment effect using baseline IOP values.
When study eyes were divided into three
groups according to the baseline IOP
(C19 mmHg, C15 to \19 mmHg, or
\15 mmHg), all groups had significant IOP
reductions from baseline at 4, 8, and 12 weeks
after switching to Duotrav. Previous studies
evaluating the efficacy of switching to fixed
drug therapy were conducted primarily in eyes
with a baseline IOP of C20 mmHg or in those
with C19 mmHg for studies of Duotrav [10, 12,
13]. In the present study, significant IOP
reductions were observed in eyes with a
baseline IOP of\19 mmHg and even in those
with\15 mmHg, suggesting that NTG patients
with normal IOP who experience a progression
of visual field defects despite PGA monotherapy
might also be good candidates for Duotrav
therapy.
During the study, close monitoring was
performed for SPK and conjunctival
hyperemia, the most common side effects of
PGA-containing ophthalmic treatments. Side
effects were scored according to the NEI
classification system and with reference to
sample pictures. After the initiation of Duotrav
therapy, SPK and conjunctival hyperemia scores
showed no significant worsening over time.
Based on these results, the effects of Duotrav on
the ocular surface were considered minimal in
the present study population, including dry
eyes. SPK has been reported at a higher
frequency in patients using timolol
ophthalmic solution [28, 29] and might be
caused by the presence of BAK in the timolol
solution [30, 31]. This preservative has strong
antimicrobial activity but adversely affects the
ocular surface [32, 33]. Adverse effects on the
ocular surface may therefore be reduced by
choosing a BAK-free regimen [20, 34]. Duotrav
is a fixed-combination ophthalmic solution of
travoprost and timolol and free of BAK, whereas
combination regimens using separate
ophthalmic solutions of travoprost and
timolol or using other fixed drugs are
associated with exposure to BAK because
except for travoprost, they all contain BAK.
Duotrav contains polyquaternium-1 an
alternative that is less toxic to the cornea than
BAK [35]. There have been few studies on the
effects of polyquaternium-1 in clinical practice
but the present study suggests the advantage of
using this compound as a preservative.
No serious adverse events were reported
during Duotrav therapy but adverse events in
six patients led to treatment discontinuation
either at the patient’s request or at the doctor’s
discretion, clearly suggesting that individual
Table 5 Cumulative incidence rates of eyelash changes, blepharal pigmentation, and deepening of the eyelid sulcus
Adverse event 4 weeks 8 weeks 12 weeks
Eyelash change, n (%) 21 (13.4%) 30 (19.1%) 42 (26.8%)
Blepharal pigmentation, n (%) 19 (12.1%) 26 (16.6%) 29 (18.5%)
Deeping of the eyelid sulcus, n (%) 7 (4.5%) 9 (5.7%) 13 (8.3%)
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patients should be closely monitored. The
cumulative incidence of eyelash changes,
blepharal pigmentation and deepening of the
eyelid sulcus increased throughout the study
period. This suggests that it is important to
instruct patients to remove any solution spilled
on the eyelid skin by wiping or washing their
face after the administration of Duotrav. There
were no significant changes from baseline in the
mean blood pressure or pulse rate after
treatment did not change significantly.
This study had some limitations. The
number of cases analyzed was relatively small,
especially when the cases were divided into
three groups, and using a larger number of
patients would increase the statistical power.
However, the results observed in this study
showed a significant reduction of IOP. The open
label and no control design might also
introduce unconscious bias into some of the
findings. The lack of washout phase before
switching to Duotrav may be considered
another limitation of this study. Therefore, we
analyzed the IOP reduction from baseline at
12 weeks using multiple regression analysis and
previous treatment was likely to be completely
washed out at 12 weeks.
CONCLUSIONS
Duotrav appears to be a useful treatment as it
exhibited a good IOP-lowering effect regardless
of pretreatment IOP, and was associated with
few adverse events. However, a multiple
regression analysis identified baseline IOP and
the type of PGA used in prior treatment as
significant predictors of the magnitude of IOP
reduction. This indicates that the magnitude of
the effect of Duotrav is influenced by the
pretreatment IOP; however, further analysis is
required to determine the effect of PGA type. In
the second report of this study, we will describe
the analysis of our data by prior PGA
monotherapy.
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